
Uterine cancer (also known as womb cancer) is primarily divided into endometrial cancer, which starts in the uterine lining, and the rarer, more aggressive uterine sarcoma, which starts in the muscle or connective tissue. Treatment protocols are highly individualized based on molecular testing, with a strong emphasis on minimally invasive surgery and targeted immunotherapies for advanced cases.
Abnormal Bleeding: Any vaginal bleeding, spotting, or discharge after menopause is the most significant warning sign.
Irregular Periods: Unusually heavy bleeding or bleeding between periods in those who have not reached menopause.
Pelvic Pain: Persistent pain or pressure in the pelvic region that does not resolve.
Urinary Changes: Difficulty or pain during urination, or the presence of a persistent pelvic mass.
Dyspareunia: Pain or discomfort experienced during sexual intercourse.
Systemic Signs: Unintentional weight loss or persistent fatigue associated with pelvic symptoms.
Total Hysterectomy: The most common surgery, involving the removal of the entire uterus and cervix; often performed robotically.
Bilateral Salpingo-Oophorectomy (BSO): Removal of both ovaries and fallopian tubes to prevent recurrence, as ovaries produce estrogen that can fuel tumor growth.
Sentinel Lymph Node (SLN) Mapping: A precise technique using fluorescent dye to identify and remove only the first few "gatekeeper" lymph nodes.
Lymphadenectomy: More extensive removal of pelvic and para-aortic lymph nodes if cancer spread is suspected.
Radical Hysterectomy: Required if cancer has reached the cervix; includes removal of the uterus, cervix, parametrium, and upper vagina.
Vaginal Brachytherapy (Internal): A radioactive source is placed inside a cylinder and inserted into the vagina for short, highly localized sessions.
External Beam Radiation (EBRT): A machine directs X-rays at the pelvic area, typically scheduled daily for 4 to 6 weeks.
IMRT: A specialized radiation therapy that shapes beams to the tumor, sparing the bladder and bowel from unnecessary exposure.
Proton Therapy: Used in specific high-risk cases to further reduce the "exit dose" of radiation to surrounding healthy tissue.
Chemotherapy: IV drug combinations like Carboplatin and Paclitaxel used for high-grade or metastatic disease.
Hormone Therapy: Uses progestins to block estrogen receptors, often used for low-grade tumors in patients wishing to preserve fertility.
Immunotherapy: Drugs like Pembrolizumab or Dostarlimab that help the immune system attack cancer, especially in specific genetic profiles.
Targeted Therapy: Medications such as Lenvatinib that block the blood supply to tumors, often paired with immunotherapy for a dual attack.
Molecular Profiling: Testing the tumor biopsy for specific markers to determine if immunotherapy will be more effective than chemo.
Imaging Workup: Completing an MRI or CT scan to check the depth of "myometrial invasion" (how deep the cancer has grown into the muscle).
Physical Optimization: Engaging in light activity to improve cardiovascular health before the abdominal procedure.
Bowel Prep: Following specific liquid diets or bowel cleansing instructions if required by the surgical team.
Fertility Discussion: For younger patients, discussing hormonal sparing options or egg freezing before a hysterectomy.
Endometrial Biopsy: To confirm the type and grade of the cancer (Endometrioid vs. Serous vs. Sarcoma).
Transvaginal Ultrasound: To measure the thickness of the uterine lining and check the condition of the ovaries.
Chest X-ray or CT: To ensure the cancer has not migrated to the lungs or upper abdomen.
CA-125 Blood Test: While not always definitive, it can help track treatment response in certain advanced types.
Complete Blood Count (CBC): To check for anemia, which is common in patients experiencing heavy vaginal bleeding.
Menopause Management: If ovaries were removed, you may experience hot flashes; non-hormonal management strategies are often prioritized.
Lymphedema Vigilance: Monitoring for swelling in the legs if pelvic lymph nodes were removed; early physical therapy is key.
Vaginal Health: Using specialized moisturizers or dilators if radiation therapy caused narrowing or dryness of the vaginal canal.
Surveillance Schedule: Regular pelvic exams and scans every 3–6 months for the first 2 years to ensure the surgical site remains clear.
Support Systems: Connecting with survivorship programs to manage the emotional impact of a hysterectomy and changes in body image.
High Cure Rates: Most Stage I endometrial cancers have a 5-year survival rate exceeding 90%.
Fertility Sparing: Modern protocols may allow progestin-only therapy for very early cases in young women who wish to preserve fertility.
Precision Mapping: Sentinel node mapping reduces the risk of permanent leg swelling (lymphedema) by over 50%.
Targeted Success: Immunotherapy has significantly improved survival times for patients with specific genetic markers.
Rapid Recovery: Minimally invasive robotic surgery often allows patients to return home within 24–48 hours.